Printer Friendly

Mylan reports financial results for nine months ended 30 September 2016.

M2 PHARMA-November 10, 2016-Mylan reports financial results for nine months ended 30 September 2016

(C)2016 M2 COMMUNICATIONS

United States-based speciality pharmaceuticals company, Mylan NV (NASDAQ, TASE: MYL), has reported its financial results for nine months ended 30 September 2016, it was reported yesterday.

The company reported total revenues and adjusted total revenues of USD7.81bn for the nine months ended September 2016, an increase of 13% and 12%, respectively, compared to the prior year period.

Generics segment third party net sales were USD6.68 billion, up 12% on a US GAAP and adjusted basis when compared to the prior year period.

Specialty segment third party net sales were USD1.07 billion, up 12% compared to the prior year period

The firm posted US GAAP cash provided by operating activities of USD1.70bn in the nine months ended September 2016, an increase of 25% against the year-ago period.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Nov 10, 2016
Words:159
Previous Article:Researchers at University of Illinois discover monobody that can block oncogene's activity.
Next Article:TransEnterix Partners with Getz Healthcare to Lead Robotic Sales, Service and Support.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters